Top Story

Diverse gut microbiome may improve response to immunotherapy for melanoma

Diverse gut microbiome may improve response to immunotherapy for melanoma
February 21, 2017

Patients with melanoma who responded to immunotherapy had a more diverse gut microbiome than nonresponders, according to study results scheduled for presentation at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.

These results suggest that modifications to the gut microbiome could potentially improve a patient’s response to anti–PD-1 therapy.

In the Journals

Physical activity reduces risk for breast cancer recurrence

February 21, 2017
Exercising is the most important lifestyle change a woman can make to prevent breast cancer recurrence and mortality, according to a systematic review recently published…
FDA News

FDA grants priority review to inotuzumab ozogamicin for ALL

February 21, 2017
The FDA granted priority review to inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according…
In the Journals PlusPerspective

Alternating treatment fails to delay progression of advanced renal cell carcinoma

February 21, 2017
An 8-week treatment rotation of pazopanib and everolimus failed to improve survival or quality of life in patients with advanced renal cell carcinoma, according to…
Curbside Consultation

Managing Hypoechoic Pancreatic Lesions: Follow-up EUS vs. FNA

Healio Gastroenterology, February 2017
Jason B. Samarasena, MD; Kenneth J. Chang, MD, FACG, FASGE
A: First, it is important to describe what a vague hypoechoic lesion of the pancreas means to an endosonographer (Figure 1). Any lesion that is large, well…
More News Headlines »

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
Meeting News

VIDEO: Down syndrome does not affect management of pediatric ALL

January 5, 2017
More »

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Current Issues
View the Current Issue
HemOnc Today